This roundup has some really interesting and clinically relevant  articles.  The first one, from Palomo and colleagues, evaluates risk for cardiovascular malformations in children prenatally exposed to lithium.  Yang and colleagues look at neonatal discontinuation [...]
In 2016, the American Academy of Pediatrics (AAP) issued new infant sleep guidelines,  recommending that  infants should sleep in the same room as their parents – on a separate firm sleep surface, such as a [...]
We’ve all heard it: Breast is Best.  We all know what it means.  And if you have had a baby at some point over the last ten years, you have been encouraged, and maybe even [...]
Sometimes a weekly roundup turns into a monthly roundup.  Sorry about that.  From  the PACT Consortium, we have a study defining distinct subtypes of perinatal depression which differ in terms of severity and timing of [...]
Earlier this week, a deadly explosion erupted at an arena in Manchester, England, where the American pop singer Ariana Grande was performing. Â One of the most horrifying aspects of the Manchester bombing is that this [...]
It is clear that screening for perinatal depression substantially improves detection; however, screening alone does not appear to improve rates of treatment or outcomes. Â What we find is that many, if not most, women with [...]
 There have long been concerns regarding the use of the anticonvulsant valproate (Depakote) during pregnancy.  First trimester use of valproate has been associated with a 3-5% risk of neural tube defects, as well as [...]
PMDD or premenstrual dysphoric disorder has always been a bit of mystery. Â We explain that PMDD is triggered by changes in reproductive hormone levels, but when you look at hormone levels in women with PMDD, [...]
According to data from the 2002-2015 National Survey on Drug Use and Health, the prevalence of marijuana use was 3.8% in pregnant women (n=14,400), compared to 7.5% in nonpregnant women (n=395,600). Â Â The investigators observed that [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression. Â SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. Â This drug was initially under [...]
